In the randomized Phase 2 OpACIN-neo trial evaluating the efficacy of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma, high tumor mutational burden and high interferon-gamma-related gene expression were associated with pathologic response and low risk of relapse.19 However, tumor PD-L1 expression was not associated with pathological response to neoadjuvant immunotherapy.20 This evidence concerns the gene IFNG and neoplasm.